- Advertise
- Contact Editorial
- Editorial Submission Guidelines
- Contact MJH Life Sciences
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharmaceutical Executive-10-01-2016
Pharmaceutical Executive
Content Marketing’s Data Fail: Information Without Insight?
October 24, 2016
Features
36
10
A practical roadmap for pharma brand teams in avoiding the pitfalls in statistical thinking when appraising and presenting data.
The Rise of the CFO Strategist: Balancing Numbers and Know-how
October 24, 2016
Features
36
10
Today’s C-suite executives in the life sciences must be experts in many disciplines. Pharm Exec examines the evolving role of the chief financial officer as not just a numbers and bottom-line risk manager but an integral contributor to overall corporate strategy and close partner to the CEO.
Steps Toward Rare Disease Success
October 20, 2016
Columns
36
10
When lobbying tips the scales: a path to drug approval.
‘Huge Sellers’ Herald Changes in Japan Drug Pricing
October 13, 2016
Features
36
10
The latest price rules revision is both radical and rare by the government’s usual exhaustive standards. What do the new rules mean for pharma players in the world’s third-largest market?
Real-World Evidence: From Volume to Value
October 13, 2016
Features
36
10
Pharm Exec convenes an expert Roundtable to discuss one of the hottest topics in big data today-how to make that data relevant to payers, regulators and the patient through reliance on real-world evidence in driving better health outcomes.
Are You Winning or Losing in Pharma 2.0?
October 13, 2016
Columns
36
10
Answer 12 key questions to determine if your brand team is leveraging today’s winning competitive strategies and actions.
Pharma and the Peril of Europe’s Trade Policies
October 12, 2016
Columns
36
10
The potential collapse of the CETA agreement jeopardizes EU’s overall trade footing.
Prospects, Analysis and Trends in Global Pharma 2016
October 11, 2016
From the Editor
36
10
Highlighting the seven key trends in global pharma that drove discussion at this year's CPhI Worldwide event in Spain.
New Challenge to IP Innovation
October 01, 2016
Columns
36
10
Survey on the rising use of Inter Partes Reviews to challenge patents reveals key considerations for originator companies.
Major Changes Ahead for Drug User Fees
October 01, 2016
Columns
36
10
PDUFA VI to enhance FDA staffing, revise fees and expand evidence for drug development.
Country Report: Czech Republic
October 01, 2016
Special Sponsored Section
36
10
Though comparatively smaller when positioned against some of the country’s neighbors, the pharmaceutical market in the Czech Republic finds itself on a solid growth trajectory, with innovator drug developers grabbing a larger piece of the value pie in the traditionally generics- dominated setting.
Pharmaceutical Executive, October 2016 Issue (PDF)
October 01, 2016
Issue PDF
36
10
Click the title above to open the Pharmaceutical Executive October 2016 issue in an interactive PDF format.